Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells

[1]  Hiroshi Yamamoto,et al.  Advanced Glycation End Products-driven Angiogenesis in Vitro , 1997, The Journal of Biological Chemistry.

[2]  H. Yamamoto,et al.  Participation of c-met in the progression of human gastric cancers: anti-c-met oligonucleotides inhibit proliferation or invasiveness of gastric cancer cells. , 1996, Cancer gene therapy.

[3]  L. Iacoviello,et al.  Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture , 1996, Diabetologia.

[4]  Nigel Mackman,et al.  Elevated Cyclic AMP Inhibits NF-κB-mediated Transcription in Human Monocytic Cells and Endothelial Cells* , 1996, The Journal of Biological Chemistry.

[5]  V. Martina,et al.  PAI-1 reduction after treatment with glutathione in NIDDM , 1996 .

[6]  Hiroshi Yamamoto,et al.  Advanced glycosylation end products stimulate the growth but inhibit the prostacyclin‐producing ability of endothelial cells through interactions with their receptors , 1996, FEBS letters.

[7]  Yasuhiko Hayashi,et al.  Possible Participation of Autocrine and Paracrine Vascular Endothelial Growth Factors in Hypoxia-induced Proliferation of Endothelial Cells and Pericytes (*) , 1995, The Journal of Biological Chemistry.

[8]  H. Yamamoto,et al.  Receptor-mediated toxicity to pericytes of advanced glycosylation end products: a possible mechanism of pericyte loss in diabetic microangiopathy. , 1995, Biochemical and biophysical research communications.

[9]  畠山 治彦.  Vascular aldosterone : biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells , 1995 .

[10]  Hiroshi Yamamoto,et al.  Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. , 1994 .

[11]  A. Schmidt,et al.  Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Y. Zou,et al.  Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.

[13]  H. Yamamoto,et al.  Endothelin 1 mediates endothelial cell-dependent proliferation of vascular pericytes. , 1993, Biochemical and biophysical research communications.

[14]  H. Yamamoto,et al.  Vascular pericytes not only regulate growth, but also preserve prostacyclin-producing ability and protect against lipid peroxide-induced injury of co-cultured endothelial cells. , 1993, Biochemical and biophysical research communications.

[15]  E. Cagliero,et al.  Increased Expression of Tissue Plasminogen Activator and Its Inhibitor and Reduced Fibrinolytic Potential of Human Endothelial Cells Cultured in Elevated Glucose , 1992, Diabetes.

[16]  S. Dawson,et al.  The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. , 1992, Atherosclerosis.

[17]  L. Nelles,et al.  Interaction of AP-1-, AP-2-, and Sp1-like proteins with two distinct sites in the upstream regulatory region of the plasminogen activator inhibitor-1 gene mediates the phorbol 12-myristate 13-acetate response. , 1992, Journal of Biological Chemistry.

[18]  R. Bucala,et al.  Immunochemical detection of advanced glycosylation end products in vivo. , 1992, The Journal of biological chemistry.

[19]  P. Bosma,et al.  Role of protein kinase C and cyclic adenosine monophosphate in the regulation of tissue-type plasminogen activator, plasminogen activator inhibitor-1, and platelet-derived growth factor mRNA levels in human endothelial cells. Possible involvement of proto-oncogenes c-jun and c-fos. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[20]  H. Yasuda,et al.  Purification and characterization of tissue plasminogen activator secreted by human embryonic lung diploid fibroblasts, IMR-90 cells. , 1991, Agricultural and biological chemistry.

[21]  K. Hajjar,et al.  Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. , 1991, The Journal of biological chemistry.

[22]  H. Vlassara.  Chronic Diabetic Complications and Tissue Glycosylation: Relevant Concern for Diabetes-Prone Black Population , 1990, Diabetes Care.

[23]  G. Lowe,et al.  Tissue Plasminogen Activator Inhibition in Diabetes Mellitus , 1989, Diabetes Care.

[24]  E. Levin,et al.  Cyclic AMP potentiates phorbol ester stimulation of tissue plasminogen activator release and inhibits secretion of plasminogen activator inhibitor-1 from human endothelial cells. , 1988, The Journal of biological chemistry.

[25]  A. Cerami,et al.  Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.

[26]  J. Auwerx,et al.  Tissue‐Type Plasminogen Activator Antigen and Plasminogen Activator Inhibitor in Diabetes Mellitus , 1988, Arteriosclerosis.

[27]  M. Blombäck,et al.  PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.

[28]  D. Loskutoff,et al.  Structure of the human plasminogen activator inhibitor 1 gene: nonrandom distribution of introns. , 1987, Biochemistry.

[29]  B. Binder,et al.  Nonenzymatic glucosylation as a contributing factor to defective fibrinolysis in diabetes mellitus. , 1986, Haemostasis.

[30]  J. Paramo,et al.  Postoperative Changes in the Plasmatic Levels of Tissue-Type Plasminogen Activator and Its Fast-Acting Inhibitor - Relationship to Deep Vein Thrombosis and Influence of Prophylaxis , 1985, Thrombosis and Haemostasis.

[31]  F. Werf,et al.  Plasminogen activator inhibitor in the blood of patients with coronary artery disease. , 1985, British medical journal.

[32]  R. S. Kent,et al.  Effect of hydrogen peroxide on prostaglandin production and cellular integrity in cultured porcine aortic endothelial cells. , 1985, The Journal of clinical investigation.

[33]  P. Verde,et al.  The human urokinase-plasminogen activator gene and its promoter. , 1985, Nucleic acids research.

[34]  E. Kruithof,et al.  Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. , 1984, Blood.

[35]  K. Pritchard,et al.  Restoration of Prostacyclin/Thromboxane A2 Balance in the Diabetic Rat: Influence of Dietary Vitamin E , 1982, Diabetes.

[36]  R. Gorman,et al.  Regulation of endothelial cell cyclic nucleotide metabolism by prostacyclin. , 1981, The Journal of clinical investigation.

[37]  C. Dollery,et al.  CIRCULATING PROSTACYCLIN MAY BE REDUCED IN DIABETES , 1979, The Lancet.

[38]  Daniel L. McGee,et al.  Diabetes and cardiovascular disease. The Framingham study. , 1979, JAMA.

[39]  J. Vane,et al.  Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. , 1978, Pharmacological reviews.

[40]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[41]  P. Lefèbvre,et al.  [Eye and the diabetes mellitus]. , 1971, Archives d'ophtalmologie et revue generale d'ophtalmologie.

[42]  B. Binder,et al.  Plasminogen Activation in Diabetes mellitus , 1988 .

[43]  A. Cerami,et al.  The biochemistry of the complications of diabetes mellitus. , 1981, Annual review of biochemistry.